Needham Reiterates Buy on NeoGenomics, Maintains $19 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson has reiterated a Buy rating on NeoGenomics (NASDAQ:NEO) and maintained a price target of $19.
September 25, 2024 | 9:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Mike Matson has reiterated a Buy rating on NeoGenomics and maintained a price target of $19, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $19 price target by a reputable analyst suggests a positive outlook for NeoGenomics. This could lead to increased investor confidence and potentially a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100